While the threshold of 750,000 victims of Covid-19 has been crossed, orders for vaccines are multiplying from major pharmaceutical laboratories. The pace of “deals” has accelerated in recent days, in particular on the Old Continent, after a start-up delay. Last Friday, Europe signed the reservation of 400 million doses to the Anglo-Swedish AstraZeneca, which could start its deliveries at the end of 2020. This agreement, which is the first to be signed by the European Commission, had been in the pipes since the mid-June.
Read also: Coronavirus: why the Russian vaccine "Sputnik V" is not leading the planetary race
Another Big Pharma, Johnson & Johnson (J&J), has announced that it has entered into negotiations with the European Union regarding the reservation of 200 million doses, with an option for an additional 200 million. A week earlier, the US laboratory, which would be able to produce up to 1 billion doses by the end of 2021, had sealed with the US government an agreement worth $ 1 billion for 100 million d 'injections.
This article is for subscribers only. You have 71% left to discover.
Subscribe: 1 € for 2 months
Can be canceled at any time
Enter your emailAlready subscribed? Log in
